- July 01, 2024
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Establishes New Company, Arirge Co., Ltd., to Address Social Issues Related to Cancer
Taiho Pharmaceutical Co., Ltd. announced today that it has established a new company, Arirge Co., Ltd., dedicated to addressing social issues related to cancer by offering solutions other than pharmaceutical products.
As a company closely involved with human life, and with over 50 years of experience in developing and delivering anti-cancer drugs, Taiho Pharmaceutical has also been confronting social issues related to cancer that cannot be resolved with pharmaceutical products alone. To address these issues more intensively, Taiho Pharmaceutical has established this new company. Arirge will leverage Taiho Pharmaceutical’s extensive expertise, experience, and know-how in oncology to provide a broad range of solutions. These include Arirge LEARNING, an educational portal site already available from January 2024 which offer services to support balancing between cancer treatment and work. Going forward, Arirge will also provide Arirge SUPPORT, a cloud service designed to help companies support their employees’ return to work and furthermore to manage the balance between treatment and work, and other services to promote cancer screening and smoking cessation.
Taiho Pharmaceutical, together with Arirge, aims to make greater contributions to solving social issues related to cancer so that cancer patients and their families can continue to enjoy the precious moments of daily life, today and every day.
Overview of Arirge Co., Ltd.
Company Name |
Arirge Co., Ltd. |
Representative | Masayuki Morishita, Representative Director |
Location | Chiyoda-ku, Tokyo |
Established | June 6, 2024 |
Business |
Provision of information, software, and platform services related to healthcare and medical care |
Corporate Website |
https://www.arirge.co.jp (only in Japanese) |
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.